Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.

P-117: Gene Expression and Developmental State of Mouse Cloned Embryos after Treatment with Histone Deacetylase Inhibitor,Suberoylanilide Hydroxamic Acid (SAHA)

Background: It is known that acetylation level of the nuclear histones in cloned embryos is lower compare to normally developed embryos. Histone deacetylas inhibitors (HDACi) with improvement of acetylation level in these embryos can affect embryo quality in pre-implantation stage and expression level of different genes especially developmental genes. Materials and Methods: In this research, SA...

Pharmacological Inhibition of Histone Deacetylases (HDACs) by Suberoylanilide Hydroxamic Acid (SAHA) Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain

Novel N-hydroxybenzamide histone deacetylase inhibitors as potential anti-cancer agents.

Histone deacetylases (HDACs) are a class of Zn(2+) dependent metalloproteases that play an important role in tumorigenesis. Inhibition of HDACs may be a potential strategy for cancer therapy. This study designed and synthesized a series of novel N-hydroxybenzamide histone deacetylase inhibitors based on the structural features of suberoylanilide hydroxamic acid (SAHA), the first HDAC inhibitor ...

Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells.

Inhibitors of histone deacetylases, including suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), are emerging anticancer agents. In the current study, we examined the cytoprotective effects of these agents. Cisplatin induced 40-50% apoptosis in rat kidney proximal tubular cells in 18 h, which was suppressed to 20-30% by 1-5 microM SAHA or 0.1 microM TSA. Consistently, SAHA partial...

Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.

Pharmacological manipulation of gene expression is considered a promising avenue to reduce postischemic brain damage. Histone deacetylases (HDACs) play a central role in epigenetic regulation of transcription, and inhibitors of HDACs are emerging as neuroprotective agents. In this study, we investigated the effect of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) on histone acetylati...